In an unusual alliance of giants, J&J is paying an unspecified amount of cash to partner with Bristol-Myers on BMS-986177, a Factor XIa inhibitor being developed as an anticoagulant to prevent thrombotic events.
The pharma players plan to jointly commit cash and expertise to a “broad” development program covering multiple indications and then share any profits that come out of the work. And they’re working on observations that beating back the level of thrombin can reduce the risk of heart attack, stroke and peripheral artery disease.
Researchers will be building on some data gathered in a hemophilia C study which demonstrated that a low level of FXIa was tied to reduced incidents of cardio disease, with the opposite true in spurring a higher rate of problems.
The drug is now headed into Phase II later this year for secondary stroke.
Big cardio drugs are neither easy or cheap to produce, and the risk of failure runs high with a rising set of hurdles on efficacy and safety from payers.
Noted Bristol-Myers research chief Tom Lynch:
“By combining the strength of our companies’ extensive expertise in the development and commercialization of cardiovascular treatments, we can maximize the potential of FXIa inhibition.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription